Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5AP | P20292 | 19/20 | 1.00 |
| ▸ | ALOX5 | P09917 | 7/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 2/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.76 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Quiflapon SCHEMBL30505315 | 1.00 | ALOX5AP (1.00) | ALOX5APALOX5CYP3A4CYP2C9CYP2D6 | |
| Quiflapon SCHEMBL29372303 | 1.00 | ALOX5AP (1.00) | ALOX5APALOX5CYP3A4CYP2C9CYP2D6 | |
| Quiflapon SCHEMBL29370879 | 1.00 | ALOX5AP (1.00) | ALOX5APALOX5CYP3A4CYP2C9CYP2D6 | |
| Quiflapon SCHEMBL9306842 | 0.99 | ALOX5AP (0.98) | ALOX5APALOX5CYP3A4CYP2C9CYP2D6 | |
| Quiflapon SCHEMBL9306864 | 0.99 | ALOX5AP (0.98) | ALOX5APALOX5CYP3A4CYP2C9CYP2D6 | |
| SCHEMBL2109210 | 0.95 | ALOX5AP (1.00) | ALOX5APALOX5CYP3A4CYP2C9CYP2D6 | |
| SCHEMBL2108829 | 0.94 | ALOX5AP (0.89) | ALOX5APALOX5CYP3A4CYP2C9CYP2D6 | |
| SCHEMBL27899653 | 0.94 | ALOX5AP (0.88) | ALOX5APALOX5CYP3A4CYP2C9CYP2D6 | |
| SCHEMBL9185735 | 0.93 | ALOX5AP (0.86) | ALOX5APALOX5CYP3A4CYP2C9CYP2D6 | |
| Quiflapon SCHEMBL1229503 | 0.93 | ALOX5AP (1.00) | ALOX5APALOX5CYP3A4CYP2C9CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 644 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11136342-B2 | Carbonate prodrugs and methods of using the same | ACORDA THERAPEUTICS, INC. (US) | 2021-10-05 | — | — | US | claimed |
| US-10919934-B2 | Compositions and methods for managing respiratory conditions | EMORY UNIVERSITY (US) | 2021-02-16 | — | — | US | claimed |
| US-20200331965-A1 | Compositions and Methods for Managing Respiratory Conditions | UNIV EMORY (US) | 2020-10-22 | — | — | US | claimed |
| US-20200157126-A1 | CARBONATE PRODRUGS AND METHODS OF USING THE SAME | ACORDA THERAPEUTICS, INC. | 2020-05-21 | — | — | US | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-8980918-B2 | Amorphous (5-fluoro-2-methyl-3-quinolin-2-ylmethyl-indol-1-yl)-acetic acid | ATOPIX THERAPEUTICS LIMITED (GB) | 2015-03-17 | — | — | US | claimed |
| US-8703956-B2 | Amorphous (5-fluoro-2-methyl-3-quinolin-2-ylmethyl-indol-1-yl)-acetic acid | ATOPIX THERAPEUTICS LIMITED (GB) | 2014-04-22 | — | — | US | claimed |
| US-8268352-B2 | Modified release composition for highly soluble drugs | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-18 | — | — | US | claimed |
| US-20120232031-A1 | INJECTABLE FORMULATIONS FOR INTRA-ARTICULAR OR PERI-ARTICULAR ADMINISTRATION | PANMIRA PHARMACEUTICALS, LLC (US) | 2012-09-13 | — | — | US | claimed |
| US-8263125-B2 | Dosage form for high dose-high solubility active ingredients that provides for immediate release and modified release of the active ingredients | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-11 | — | — | US | claimed |
| EP-0419049-B1 | (Quinolin-2-ylmethoxy) indoles as inhibitors of the biosynthesis of leukotrienes | MERCK FROSST CANADA INC (CA) | 1995-04-12 | — | — | EP | claimed |
| WO-1994013293-A2 | (QUINOLIN-2-YLMETHOXY)INDOLES AS INHIBITORS OF THE BIOSYNTHESIS OF LEUKOTRIENES | MERCK FROSST CANADA INC. (CA) | 1994-06-23 | — | — | WO | claimed |
| US-5321033-A | Anti-asthmatic, anti-allergenic or cryptoprotective | MERCK FROSST CANADA, INC. | 1994-06-14 | — | — | US | claimed |
| US-5272145-A | (Quinolin-2-ylmethoxy)indoles as inhibitors of the biosynthesis of leukotrienes | MERCK FROSST CANADA, INC. (CA) | 1993-12-21 | — | — | US | claimed |
| US-5254541-A | (Quinolin-2-ylmethoxy)indole/cyclodextrin complex | MERCK FROSST CANADA, INC. (CA) | 1993-10-19 | — | — | US | claimed |
| US-5254567-A | Antihistamines, antiinflammatory agent, antiallergens, cytoprotective agent | MERCK FROSST CANADA, INC. (CA) | 1993-10-19 | — | — | US | claimed |
| WO-1993010115-A1 | AMORPHOUS (QUINOLIN-2-YLMETHOXY) INDOLES AS LEUKOTRIENE ANTAGONISTS | MERCK FROSST CANADA INC. (CA) | 1993-05-27 | — | — | WO | claimed |
| EP-0542356-A1 | (Quinolin-2-ylmethoxy) indole/cyclodextrin complex as leukotrien inhibitor | MERCK FROSST CANADA INC. (CA) | 1993-05-19 | — | — | EP | claimed |
| US-5204344-A | (Quinolin-2-ylmethoxy)indoles as inhibitors of the biosynthesis of leukotrienes | MERCK FROSST CANADA, INC. (CA) | 1993-04-20 | — | — | US | claimed |
| EP-0419049-A1 | (Quinolin-2-ylmethoxy) indoles as inhibitors of the biosynthesis of leukotrienes | MERCK FROSST CANADA INC. (CA) | 1991-03-27 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10919934-B2 | Compositions and methods for managing respiratory conditions | EPCAM, ANXA5, CFTR | ALOX5AP 1006/4885ALOX5 404/4885CYP3A4 4814/4885 |
| US-20200157126-A1 | CARBONATE PRODRUGS AND METHODS OF USING THE SAME | CA6, CA7, CA4 | ALOX5AP 959/4885ALOX5 946/4885CYP3A4 135/4885 |
| US-11136342-B2 | Carbonate prodrugs and methods of using the same | CA6, CA7, CA4 | ALOX5AP 959/4885ALOX5 946/4885CYP3A4 135/4885 |
| US-20200331965-A1 | Compositions and Methods for Managing Respiratory Conditions | EPCAM, ANXA5, CFTR | ALOX5AP 1006/4885ALOX5 404/4885CYP3A4 4814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.